Health Canada And FDA Issue Adverse Reaction Updates In Second Half Of 2010 Which Involve Popular Drug Zocor (Simvastatin)

Cases Of Interstitial Lung Disease (ILD) And Rhabdomyolysis / Myopathy Associated With Cholesterol Drugs Known As Statins, Including Zocor 

(Posted by Tom Lamb at DrugInjuryWatch.com)

_________________________________________________________________________________________

UPDATE:  FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury

[06-08-2011] The U.S. Food and Drug Administration (FDA) is recommending limiting the use of the highest approved dose of the cholesterol-lowering medication, simvastatin (80 mg) because of increased risk of muscle damage [i.e., rhabdomyolysis]….

Read more at the FDA's web page

*************************

What is rhabdomyolysis?

Rhabdomyolysis is a rare but very serious condition. It occurs when muscles are damaged and muscle cell contents are released into the bloodstream. If not detected early and treated promptly, rhabdomyolysis may result in acute renal failure, kidney damage, or other organ damage which may be fatal.

What are the symptoms of rhabdomyolysis?

Patients who develop rhabdomyolysis can have several different symptoms, but most often complain about muscle aches involving their calves, back, or their entire body. In addition to this type of muscle pain, weakness, fever, nausea, vomiting, and passing of dark urine can occur.

Free Zocor Case Evaluation 

Strictly Confidential, No Obligation.

_____________________________________________________________________

The October 2010 issue of the Canadian Adverse Reaction Newsletter (CARN) included an article "Statins and interstitial lung disease" which began with these two "Key points":

During the last 15 years, 29 cases of interstitial lung disease (ILD) suspected of being associated with statins have been published.

Health Canada has received 8 adverse reaction (AR) reports of ILD, or pathologies associated with ILD, suspected of being associated with statins.

As background, drugs in the statin "class" include Zocor (simvastatin), Pravachol (pravastatin), Lescol (fluvastatin), and Lipitor (atorvastatin).

As for "what is" interstitial lung disease, also known as parenchymal lung disease, we return to the October 2010 CARN issue:

Interstitial lung disease (ILD) is a heterogeneous group of disorders that could be acute or chronic and, if left untreated, could lead to pulmonary fibrosis and pulmonary insufficiency.  Signs and symptoms include difficulty breathing, nonproductive cough and diffuse crackles heard on auscultation.  [footnotes omitted]

As pointed out by this Health Canada CARN publication, a  systematic review of the suspected association between ILD and statins was published in a CHEST medical journal from 2008, "Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports."

About a month earlier, the FDA included Zocor on its latest list of possible drug safety concerns, "Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between April – June 2010" (Page Last Updated: 08/27/2010).
 
Specifically, the 80mg dose of Zocor (simvastatin) is listed for muscle injury, with this status: "FDA is continuing to evaluate this issue to determine the need for any regulatory action."

As you may recall, it was a March 2010 FDA Drug Safety Communication, "Ongoing Safety Review of High-dose Zocor (simvastatin) and Increased Risk of Muscle Injury", that initially indicated the FDA is concerned about an increased risk myopathy and rhabdomyolysis — which is sometimes called "rhabdo" as its short name — in patients using the highest dose of Zocor, 80mg.

We will continue to monitor the safety profiles of the statin drugs, and Zocor in particular, and report any significant developments, here.

Meanwhile, if you or someone you know has developed interstitial lung disease (ILD) while using a cholesterol drug in the statin class or suffered rhabdomyolysis (rhabdo) while using Zocor 80mg daily, you may want to share your experience or information by submitting a Comment, below.

______________________________________________________________________________

DrugInjuryLaw.com: Legal Information And News About Prescription Drug Side Effects

Drug Injury Case Evaluation – Free & Confidential

2 responses to “Health Canada And FDA Issue Adverse Reaction Updates In Second Half Of 2010 Which Involve Popular Drug Zocor (Simvastatin)”

  1. Joanne Scheller Avatar
    Joanne Scheller

    My own record at Allina Clinics obtained last summer:
    CHEST X-RAY JAN 31, 1989: “Normal heart, lungs, bony structure.” EKG normal also.
    BP 140/74, pulse 72-74 & regular. Weight 141. “Grade I/VI apical systolic murmur, no specific diastolic murmur, S3, S4, rub or click audible.” Noted “mild stiffness” of right knee (I had hurt this racing a man in the Minneapolis Athletic Club pool not too much earlier).
    CHEST X-RAY MAY 3, 1994 Mpls MN: Normal heart and lungs.
    Cholesterol total 254, LDL 190. Got put on 10 mg Pravachol. Weight 174! Got off the Pravachol about a year later on my own. Don’t know why now.
    CHEST X-RAY FEB 25 1995 from Maui Memorial ER, HI: “There are minimal linear parenchymal densities diffusely throughout both lungs which from the radiographic appearance are more likely fibrosis than an acute interstitial infiltrate. There is an ill-defined area of increased density superimposed upon and obscuring the superior right hilum and the medial aspect of the mediastinum, which in vew of the intterstitial changes throughout the lungs may only be a focal area of fibrosis but either a superimposed acute infiltrate or an infiltrative neoplasm would have to be excluded. Comparison with old films of the chest is suggested for further evaluation. No other abnormalities are seen.”
    All I was told at that time was that I had “scarring” in my lungs.
    I was on and off statins since then until last May, when I caught up with what was happening to me and got off Simvastatin (the previous statin had always been Pravachol). As I write, I am on oxygen.

  2. Tom Lamb Avatar

    Joanne:
    Thank you for sharing this detailed report as regards your use of statin drugs and the fibrosis which was noted initially in your 1995 chest x-ray radiology report.
    I am presuming you have shared your past statin use with the pulmonary or other doctor(s) following you for your current lung condition. If not, I encourage you to do so and, perhaps, bring to their attention the October 2010 CARN article, above.
    I wish you the best in all aspects going forward.
    Tom Lamb

Leave a Reply to Joanne Scheller Cancel reply

Your email address will not be published. Required fields are marked *